Nurix Therapeutics, Inc. (NRIX) on GreekSoup https://greeksoup.ai/stocks/us/nrix/ Every dated entry in the public record on Nurix Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 Nurix Therapeutics, Inc.: Hansen Gwenn (Chief Scientific Officer) sold 1,452 shares (under a trading plan set in advance) at $25.00 on 15 October 2026, $36,300https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-10-15:d05db58a33Thu, 15 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: short interest 20,607,897 shares at the 15 October 2026 settlement, 9.22 days to coverhttps://greeksoup.ai/stocks/us/nrix/short-interest/us:NRIX:short-interest:2026-10-15:4ac041b0c5Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Form 144, JULIA GREGORY plans to sell 22,583 shares worth $528,528 around 14 October 2026https://greeksoup.ai/stocks/us/nrix/planned-sales/us:NRIX:planned-sale:2026-10-14:c383a2d739Wed, 14 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Gregory Julia P (Director) sold 22,583 shares at $23.40 on 14 October 2026, $528,528https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-10-14:ef0e1a4bcdWed, 14 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc. Q3 FY2026 results: revenue $673 million, net income $550 millionhttps://greeksoup.ai/stocks/us/nrix/results/fy2026-q3/us:NRIX:result:2026-10-13:494429a5a5Tue, 13 Oct 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/nrix/filings/us:NRIX:filing:2026-10-13:fe2dacbf2cTue, 13 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/nrix/filings/us:NRIX:filing:2026-10-13:24f1e477feTue, 13 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Form 144, CHRISTINE RING plans to sell 5,786 shares worth $135,045 around 2 October 2026https://greeksoup.ai/stocks/us/nrix/planned-sales/us:NRIX:planned-sale:2026-10-02:318c710763Fri, 02 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Ring Christine (Chief Legal Officer) sold 5,786 shares (under a trading plan set in advance) at $23.19 on 2 October 2026, $134,149https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-10-02:efde793fa8Fri, 02 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: short interest 17,657,588 shares at the 30 September 2026 settlement, 9.94 days to coverhttps://greeksoup.ai/stocks/us/nrix/short-interest/us:NRIX:short-interest:2026-09-30:416dd149a2Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Schedule 13G filed by Perceptive Advisors LLC, 5.3% of the classhttps://greeksoup.ai/stocks/us/nrix/holders/us:NRIX:schedule-13:2026-09-23:5607d20c01Wed, 23 Sep 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: short interest 17,976,804 shares at the 15 September 2026 settlement, 14.05 days to coverhttps://greeksoup.ai/stocks/us/nrix/short-interest/us:NRIX:short-interest:2026-09-15:fffaf4216fTue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Form 144, CHRISTINE RING plans to sell 5,787 shares worth $150,693 around 2 September 2026https://greeksoup.ai/stocks/us/nrix/planned-sales/us:NRIX:planned-sale:2026-09-02:fe2d04bf9dWed, 02 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Ring Christine (Chief Legal Officer) sold 5,387 shares (under a trading plan set in advance) at $25.69 on 2 September 2026, $138,417https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-09-02:ae4de6ad22Wed, 02 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Ring Christine (Chief Legal Officer) sold 400 shares (under a trading plan set in advance) at $26.64 on 2 September 2026, $10,655https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-09-02:348539fc63Wed, 02 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Hansen Gwenn (Chief Scientific Officer) sold 1,452 shares (under a trading plan set in advance) at $25.47 on 1 September 2026, $36,982https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-09-01:3019bfbeb2Tue, 01 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: short interest 17,950,461 shares at the 31 August 2026 settlement, 15.94 days to coverhttps://greeksoup.ai/stocks/us/nrix/short-interest/us:NRIX:short-interest:2026-08-31:dfb6a96a7cMon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Schedule 13G/A filed by Deep Track Capital, LP, 7.5% of the classhttps://greeksoup.ai/stocks/us/nrix/holders/us:NRIX:schedule-13:2026-08-14:6b11af8b91Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Schedule 13G/A filed by Redmile Group, LLC, 8.1% of the classhttps://greeksoup.ai/stocks/us/nrix/holders/us:NRIX:schedule-13:2026-08-14:72a13e39beFri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Schedule 13G filed by Rubric Capital Management LP, 7.0% of the classhttps://greeksoup.ai/stocks/us/nrix/holders/us:NRIX:schedule-13:2026-08-14:565239ea51Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Schedule 13G/A filed by Vestal Point Capital, LP, 7.8% of the classhttps://greeksoup.ai/stocks/us/nrix/holders/us:NRIX:schedule-13:2026-08-14:bcedd4b743Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Schedule 13G filed by T. Rowe Price Associates, Inc., 5.3% of the classhttps://greeksoup.ai/stocks/us/nrix/holders/us:NRIX:schedule-13:2026-08-14:0be5e3db55Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: short interest 17,984,342 shares at the 14 August 2026 settlement, 18.11 days to coverhttps://greeksoup.ai/stocks/us/nrix/short-interest/us:NRIX:short-interest:2026-08-14:59832c5076Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Form 144, GWENN HANSEN plans to sell 8,712 shares worth $215,099 around 5 August 2026https://greeksoup.ai/stocks/us/nrix/planned-sales/us:NRIX:planned-sale:2026-08-05:d9f8fd4941Wed, 05 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Hansen Gwenn (Chief Scientific Officer) sold 4,356 shares (under a trading plan set in advance) at $25.00 on 5 August 2026, $108,900https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-08-05:8f85409d71Wed, 05 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Hansen Gwenn (Chief Scientific Officer) sold 1,500 shares (under a trading plan set in advance) at $23.87 on 4 August 2026, $35,803https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-08-05:f5ed8956b9Wed, 05 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Hansen Gwenn (Chief Scientific Officer) sold 2,611 shares (under a trading plan set in advance) at $24.64 on 4 August 2026, $64,339https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-08-05:2b19c1d1d2Wed, 05 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Form 144, GWENN M HANSEN plans to sell 4,111 shares worth $95,457 around 4 August 2026https://greeksoup.ai/stocks/us/nrix/planned-sales/us:NRIX:planned-sale:2026-08-04:286e511311Tue, 04 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Form 144, JOHANNES VAN HOUTE plans to sell 4,761 shares worth $110,550 around 4 August 2026https://greeksoup.ai/stocks/us/nrix/planned-sales/us:NRIX:planned-sale:2026-08-04:8795dd97ddTue, 04 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Van Houte Hans (Chief Financial Officer) sold 1,794 shares (under a trading plan set in advance) at $23.89 on 4 August 2026, $42,861https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-08-04:9385a787a1Tue, 04 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Van Houte Hans (Chief Financial Officer) sold 2,967 shares (under a trading plan set in advance) at $24.65 on 4 August 2026, $73,129https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-08-04:2b3a3cdf0aTue, 04 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Form 144, CHRISTINE RING plans to sell 16,589 shares worth $385,031 around 3 August 2026https://greeksoup.ai/stocks/us/nrix/planned-sales/us:NRIX:planned-sale:2026-08-03:d127f1bbe6Mon, 03 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Ring Christine (Chief Legal Officer) sold 16,589 shares (under a trading plan set in advance) at $23.05 on 3 August 2026, $382,358https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-08-03:67c601efbcMon, 03 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Schedule 13G filed by Vanguard Capital Management, 5.0% of the classhttps://greeksoup.ai/stocks/us/nrix/holders/us:NRIX:schedule-13:2026-07-31:688c066e34Fri, 31 Jul 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: short interest 18,351,438 shares at the 31 July 2026 settlement, 17.99 days to coverhttps://greeksoup.ai/stocks/us/nrix/short-interest/us:NRIX:short-interest:2026-07-31:5bd2241b45Fri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Van Houte Hans (Chief Financial Officer) sold 2,845 shares at $23.38 on 30 July 2026, $66,524https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-07-30:5418dd32ecThu, 30 Jul 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Ring Christine (Chief Legal Officer) sold 3,847 shares at $23.38 on 30 July 2026, $89,954https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-07-30:4046e455aaThu, 30 Jul 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Nurix Therapeutics, Inc.: Hansen Gwenn (Chief Scientific Officer) sold 3,847 shares at $23.38 on 30 July 2026, $89,954https://greeksoup.ai/stocks/us/nrix/insiders/us:NRIX:insider:2026-07-30:93f6fa5bddThu, 30 Jul 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]>